论文部分内容阅读
目的 :探讨血脂康的调脂疗效。方法 :对 84例原发性高脂血症患者随机分为血脂康组和烟酸肌醇酯组 ,服用血脂康组 44例 ,烟酸肌醇酯组 40例 ,观察用药 8周 (wk)后血脂变化 ,并对二者进行比较。结果 :显示血脂康有较好的调脂 (降TC、TG、TC HDL ch/HDL ch及升HDL ch)作用 ,且优于烟酸肌醇酯。结论 :提示血脂康调脂疗效确切 ,服用方便 ,副作用少 ,可作为较好的临床调脂药物推广使用。
Objective: To investigate the lipid-lowering effect of Xuezhikang. Methods: Eighty-four patients with primary hyperlipidemia were randomly divided into Xuezhikang group and inositol nicotinate group. Forty-four patients in Xuezhikang group and 40 patients in inositol nicotinate group were treated with wk, After changes in blood lipids, and compare the two. Results: Xuezhikang showed better lipid-lowering effect (decreased TC, TG, TC HDL ch / HDL ch and HDL ch) and better than nicotinic acid myo-inositol. Conclusion: Suggest Xuezhikang lipid-lowering effect is exact, easy to take, less side effects, can be used as a good clinical lipid-lowering drugs to promote the use.